Thu, Jul 31, 2014, 8:40 AM EDT - U.S. Markets open in 50 mins.


% | $
Click the to save as a favorite.

MannKind Corp. Message Board

fullshred_2000 688 posts  |  Last Activity: 8 hours ago Member since: Feb 4, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • fullshred_2000 fullshred_2000 8 hours ago Flag

    Nope! Abbott Labs (AL likes the name too).

    Sentiment: Strong Buy

  • Reply to

    Trading IGXT etc

    by genedr_2000 14 hours ago
    fullshred_2000 fullshred_2000 13 hours ago Flag

    Agreed. This is a poor investment. It has value, but only time will tell what that's worth.

    Sentiment: Strong Sell

  • Reply to

    Trading IGXT etc

    by genedr_2000 14 hours ago
    fullshred_2000 fullshred_2000 14 hours ago Flag

    At least you have a strategy moving foward (and in the correct direction I might add). Most of the NitWit on this board go all-in hoping that the people that move the money will make THEM money too. Even if that means grasping at air for a couple of years. Wing and a prayer~


    Sentiment: Strong Sell

  • fullshred_2000 fullshred_2000 14 hours ago Flag

    shortsgobankrupt • Jul 8, 2014 1:19 PM

    It's the broader market macro effects, not based on news specific to IGXT. If you were a halfway decent investor you would know that. Collapsing? LoL


    Sentiment: Strong Sell

  • C'mon on baby...


    Sentiment: Strong Sell

  • fullshred_2000 fullshred_2000 Jul 30, 2014 1:15 AM Flag

    there - not "their"

  • fullshred_2000 fullshred_2000 Jul 30, 2014 1:15 AM Flag

    lol I know what you mean. I got rid of everything myself. It's almost impossible to remove things once they're out their. It's scary. Ask the people whose lives have been ruined by ripoffreportdotcom

    It's a "wonderful" site that exploits innocent people for money whose owner travels/lives with armed bodyguards 24/7.

  • fullshred_2000 fullshred_2000 Jul 30, 2014 1:08 AM Flag

    You can control that.

    Adam is a public figure. He chose that avenue. Using Twitter, FB, and dissiminating his "opinion" on TheStreet, etc. nets him a loss of privacy.

    Many people are electing to delete their aforementioned accounts because it can come back to bite them, and not in a good way.

  • fullshred_2000 fullshred_2000 Jul 30, 2014 1:02 AM Flag

    I removed his address. Rest assured it's him. Using a little detective work anyone can verify. Occassionally he posts blurbs on his Twitter account as to his whereabouts. Using that, and a couple of resources on the net, it was easy to track him down. He's living well doing what he's doing, albeit unethical and at the expense of investors and the lives of those who are waiting for, in our case, beneficial drugs.

  • fullshred_2000 fullshred_2000 Jul 30, 2014 12:53 AM Flag

    public records search

  • Pretty good for a failed analyst blogger with a bachelors degree, don't cha think??

  • Reply to

    AF to be

    by juicyjuice10001 Jul 29, 2014 11:26 PM
    fullshred_2000 fullshred_2000 Jul 30, 2014 12:38 AM Flag

    On the pdf it's Ex. X. Y, Z

  • Reply to

    AF to be

    by juicyjuice10001 Jul 29, 2014 11:26 PM
    fullshred_2000 fullshred_2000 Jul 30, 2014 12:32 AM Flag

    "CREW" citizensforethicsdotorg

    Jul 29, 2014

  • fullshred_2000 by fullshred_2000 Jul 30, 2014 12:26 AM Flag

    Similarly, in March 2014, Mr. Feuerstein published an article predicting a 60-percent chance the Food and Drug Administration (FDA) would reject the company’s new drug, Afrezza. By the end of the day, Mannkind’s shares were trading at a 10-month low. Contrary to Mr. Feurstein’s prognostication, on April 1, an FDA advisory committee granted marketing approval for Afreeza by a vote of 13 to 1.

    “Where there is smoke, there’s often fire. Maybe it’s just a coincidence that Mr. Feuerstein’s unduly negative articles appear at critical moments for these companies, but it certainly merits an investigation,” Ms. Sloan said.

    Sentiment: Strong Buy

  • Osiris Stem Cells To Compliment Mannkind's Afrezza In Disrupting Diabetes Market
    July 29, 2014 | About: MNKD +0% OSIR +0%
    Print Email

    Articles (8)
    Author's Website
    Published at Retail Investor 360: Monday, 28 July 2014 20:02 by Doctor Hung V. Tran, MD, MS

    Disclosure: I am long on MNKD.

    Due to its capacity to self-renew and give rise to cells of various lineage, mesenchymal stem cells (MSCs) have generated a great amount of enthusiasm over the past decade as a novel therapeutic paradigm for a variety of diseases. The leading, integrated stem cell company Osiris Therapeutics (NASDAQ:OSIR) thus indeed has captured and gained a significant impact in this unique market since infancy with its capabilities in groundbreaking research, development, manufacturing, marketing and distribution of stem cell products to treat unmet medical conditions in orthopedic, sport medicine and specifically wound care markets.

    [ Enlarge Image ]

    Source: Stem Cell

    Giving the diabetes mellitus market is growing at a rapid rate globally; roughly 25 million or 8.3% of the U.S. population suffer from this condition. With its FDA approved super rapid acting insulin, Afrezza, that could mimic the actions of healthy pancreas, Mannkind Corporation (NASDAQ: MNKD) is already positioned it self to become the new leader in this huge insulin market. Diabetic complications such as diabetic foot ulceration, infection, and gangrene are significant complications and the leading causes of hospitalization in patients with diabetes mellitus. We believed that Afrezza's disruptive technology to deliver Technosphere insulin via a small whistle-like device Dreamboat enabling patient's with convenience, ease of use, hence, removing barriers leading to the aforementioned complication. Regardless of Afrezza's superiority or any other potential drugs, a sizeable number of patients, not having access to care due to poverty, transportation, or rural setting would not be able to optimally control their blood sugar, thus, succumb to diabetes complications. These complications often precede lower-extremity amputation. Prompt and aggressive treatments of diabetic foot ulcers are essential to prevent exacerbation of the problem and eliminate the potential for amputation. Osiris, thus, successfully tapped into this market and established a new standard in diabetic wound care, as well as proven the tremendous impact of stem cell can have in medicine.

    Key Factors Involved in the Development of Diabetic Foot Problems

    Diabetic foot ulcer is among the most common complications of diabetes, accounting for as many as 20% of all hospitalizations in diabetic patients at an annual cost of $200 to $350 million. According to the American Diabetes Association (ADA), 15% of diabetic patients experience significant foot ulcer during their lifetime.

    Approximately 71,000 lower-extremity amputations, often sequelae of uncontrolled infection, are performed each year on diabetic patients; this represents up to 70% of all nontraumatic amputations in the United States. Also, approximately 20% of diabetics will undergo additional surgery or amputation of a second limb within 12 months of the initial amputation.

    The development of diabetic foot problems involved in three key factors: neuropathy (nerve damage), angiopathy (blood vessel disease) and ischemia (inadequate blood supply), and immunologic defects. These conditions frequently occur together and, thus, make diabetic patients more susceptible to certain types of infection and impair the patients’ ability to heal wounds adequately.

    Neuropathic changes may affect motor nerve supply of small intrinsic muscles of the foot resulting in muscular imbalance, abnormal stresses on tissues and bones, and repetitive injuries. Diminished sensory perception causes an absence of pain and unawareness of minor injuries and ulceration.

    Angiopathy and ischemia often resulted in atherosclerosis that progress more rapidly in diabetic patients. This defect can results in varying degrees of restriction of blood flow, poor circulation, and ultimately leading to skin breakdown and infection

    With immunologic defects, diabetic patients have impaired phagocytosis and intracellular microbial function that may be related to low oxygen tissue levels. These defects, thus, lead diabetic patients susceptible to infections and delayed healing.

    Sentiment: Strong Buy

  • Reply to

    Quoth the Raven = New post on SA = Cover & Buy

    by fullshred_2000 Jul 29, 2014 12:43 PM
    fullshred_2000 fullshred_2000 Jul 29, 2014 12:44 PM Flag

    "I'd contend MNKD is now at levels where you should consider your target for covering."

  • "Partnership news is, according to management, only a couple of weeks away now. Look for a continued dip this week, then start planning a cover/buy."


    Sentiment: Strong Buy

  • Job Details

    Requisition Number 14-0054
    Post Date 7/28/2014
    Title Head of Production (Sr. Director)
    City Danbury
    State CT
    Description MannKind Corporation is currently seeking a Head of Production. The incumbent is the Manufacturing Operations expert with a demonstrated in depth understanding of the individual functional areas of Commercial Manufacturing including Operations Planning, Bulk and Packaging Operations, Materials Management, Quality (cGMP), LEAN (OPex), EHS and Facilities/Maintenance. Incumbent is responsible for developing and maintaining an expanding Commercial Manufacturing Operation by developing plans for the site that aligns with the Network plan and balances short-term requirements with the long-range operating plan along with execution against the plan and achieving expected results.

    Requisition Number 14-0055
    Post Date 7/28/2014
    Title Head of Engineering (Sr. Director)
    City Danbury
    State CT
    MannKind Corporation is currently seeking a Head of Engineering Services. The Sr. Director, Engineering Services will be primarily responsible for the development and maintenance of an Engineering Services tactical plan for the Danbury site to align with the Network & Capitol plan that balances short-term requirements with the long-range operating plan (LROP). The incumbent will also develop and maintain the Danbury site “Master Plan”, participate in scenario planning, and implement capital projects as per the LROP. The Senior Director, Engineering services will work with Technical Operations, Manufacturing, and Pharm Development to develop a Capital Project plan that aligns with the Strategic plan and implement projects to meet timing, budget, and improvement targets.

    Sentiment: Strong Buy

  • Another RED day (as predicted)

    Sentiment: Strong Sell

  • versafilm • Jul 1, 2014 8:53 AM

    ".....we obtain a fair value of $2.01 per share."
    Read the H C Wainwright analysis for yourself...........1 year Target $2.00
    Sentiment: Strong Buy

    BRAH! HA HA HA!!!

    At least ONE moron bought into the hype. The rest have been bailing.

    Classic P&D


    Sentiment: Strong Sell

8.660.00(0.00%)Jul 30 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Hologic Inc.
NasdaqGSWed, Jul 30, 2014 4:00 PM EDT
Yelp, Inc.
NYSEWed, Jul 30, 2014 4:00 PM EDT